LONDON, Jan 5, 2026, 09:46 GMT — Regular session
- GSK said China approved Nucala (mepolizumab) for adults with inadequately controlled COPD with raised blood eosinophils.
- GSK shares were down about 0.3% at 1,825.5 pence by 09:45 GMT.
- Investors’ next focus is the J.P. Morgan Healthcare Conference on Jan. 13 and GSK’s full-year results on Feb. 4.
GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease (COPD). The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT.
The China nod matters because it opens a new label for one of GSK’s established respiratory drugs in a market where the company estimates around 100 million people have COPD. GSK said Nucala is the first and only monthly biologic approved in China and evaluated in COPD patients with blood eosinophil counts as low as 150 cells/µL.
A biologic is a medicine made using living cells, often engineered antibodies that target a specific pathway. In this case, GSK said Nucala is a monoclonal antibody that binds to interleukin-5, a signalling protein involved in “type 2” inflammation that can drive eosinophils — a type of white blood cell. Investegate
The approval was based on GSK’s MATINEE and METREX late-stage trials, the company said. It said mepolizumab reduced the annualised rate of moderate to severe exacerbations — flare-ups of symptoms that can trigger emergency visits or hospitalisation — versus placebo when added to inhaled triple therapy.
“There is a clear need for novel options to address COPD,” Kaivan Khavandi, GSK’s senior vice president and global head of respiratory R&D, said in the company statement. Investegate
The share move was muted, even with the regulatory win, as broader UK pharmaceuticals and biotechnology shares were also weaker early on Monday. The sector index was down about 0.6% around mid-morning, according to Sharecast data.
GSK’s stock has swung in a tight intraday band. It traded between 1,812 pence and 1,847 pence so far on Monday, compared with a 52-week high of 1,853.5 pence, according to Investing.com data.
For investors, the immediate question is commercial: how quickly Nucala can secure reimbursement and meaningful uptake in China, where COPD care has long been dominated by low-cost inhalers. Any update on launch timing and market access terms will shape near-term expectations.
The next scheduled forum for fresh detail is Jan. 13, when GSK said Tony Wood will attend the J.P. Morgan Healthcare Conference in San Francisco. Management updates there can move healthcare stocks as investors recalibrate pipeline and launch priorities.
But the biggest near-term catalyst is Feb. 4, when GSK reports full-year and fourth-quarter results. Traders will be watching for 2026 guidance and any new disclosure on how the China COPD approval feeds into the respiratory outlook.
Related articles: LSE:GSK
